Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis

Cancer Letters

Volumn 291, Issue 2, 2010, Pages 131-141

  Buxton, Iain L O ^a   Yokdang, Nucharee ^a   Matz, Robert M ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Nucleotide receptors; Secreted nucleoside diphosphate kinase B (sNDPK B); Transactivation; VEGFR2

Indexed keywords

ADP KINASE; NUCLEOTIDE; PHOSPHOTRANSFERASE; PURINE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; ENZYME RELEASE; EXTRAVASATION; HOMEOSTASIS; HUMAN; HYPOTHESIS; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 77950023386     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.021     Document Type: Review

References (170)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. (2009)
2. Coleman M.P., Quaresma M., Berrino F., Lutz J.M., De A.R., Capocaccia R., Baili P., Rachet B., Gatta G., Hakulinen T., Micheli A., Sant M., Weir H.K., Elwood J.M., Tsukuma H., Koifman S., Ga E.S., Francisci S., Santaquilani M., Verdecchia A., Storm H.H., and Young J.L. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 9 (2008) 730-756
3. Hagemeister Jr. F.B., Buzdar A.U., Luna M.A., and Blumenschein G.R. Causes of death in breast cancer: a clinicopathologic study. Cancer 46 (1980) 162-167
4. Rugo H.S. The importance of distant metastases in hormone-sensitive breast cancer. Breast 17 Suppl. 1 (2008) S3-S8
5. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
6. Retsky M., Demicheli R., Hrushesky W., Speer J., Swartzendruber D., and Wardwell R. Recent translational research: computational studies of breast cancer. Breast Cancer Res. 7 (2005) 37-40
7. Demicheli R., Retsky M.W., Hrushesky W.J., Baum M., and Gukas I.D. The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 19 (2008) 1821-1828
8. Retsky M.W., Demicheli R., Hrushesky W.J., Baum M., and Gukas I.D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116 (2008) 730-741
9. Hansen N.M., Ye X., Grube B.J., and Giuliano A.E. Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch. Surg. 139 (2004) 634-639 (discussion 639-640)
10. Peters-Engl C., Konstantiniuk P., Tausch C., Haid A., Hoffmann B., Jagoutz-Herzlinger M., Kugler F., Redtenbacher S., Roka S., Schrenk P., and Steinmassl D. The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group. Br. J. Cancer 91 (2004) 1782-1786
11. Demicheli R., Retsky M.W., Hrushesky W.J., and Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat. Clin. Pract. Oncol. 4 (2007) 699-710
12. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Cao Y., Moses M., Lane W.S., Sage E.H., and Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb. Symp. Quant. Biol. 59 (1994) 471-482
13. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
14. Zahl P.H., Maehlen J., and Welch H.G. The natural history of invasive breast cancers detected by screening mammography. Arch. Int. Med. 168 (2008) 2311-2316
15. Almog N., Ma L., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J., and Abdollahi A. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 69 (2009) 836-844
16. Alix-Panabieres C., Muller V., and Pantel K. Current status in human breast cancer micrometastasis. Curr. Opin. Oncol. 19 (2007) 558-563
17. Erbas B., Provenzano E., Armes J., and Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res. Treat. 97 (2006) 135-144
18. Sanders M.E., Schuyler P.A., Dupont W.D., and Page D.L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103 (2005) 2481-2484
19. Westfall D.P., Sedaa K.O., Shinozuka K., Bjur R.A., and Buxton I.L. ATP as a cotransmitter. Ann. NY Acad. Sci. 603 (1990) 300-310
20. Burnstock G. Purinergic signalling. Br. J. Pharamcol. 147 Suppl. 1 (2006) S172-S181
21. Burnstock G. Do some nerve cells release more than one transmitter?. Neuroscience 1 (1976) 239-248
22. Westfall D.P., Stitzel R.E., and Rowe J.N. The postjunctional effects and neural release of purine compounds in the guinea-pig vas deferens. Eur. J. Pharmacol 50 (1978) 27-38
23. Schwiebert E.M., and Zsembery A. Extracellular ATP as a signaling molecule for epithelial cells. Biochim. Biophys. Acta 1615 (2003) 7-32
24. Christofori G. New signals from the invasive front. Nature 441 (2006) 444-450
25. Muller W.A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 24 (2003) 327-334
26. Wittchen E.S. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front. Biosci. 14 (2009) 2522-2545
27. Rowe R.G., and Weiss S.J. Breaching the basement membrane: who, when and how?. Trends Cell Biol. 18 (2008) 560-574
28. Sud'ina G.F., Mirzoeva O.K., Galkina S.I., Pushkareva M.A., and Ullrich V. Involvement of ecto-ATPase and extracellular ATP in polymorphonuclear granulocyte-endothelial interactions. FEBS Lett. 423 (1998) 243-248
29. Ferrero M.E. A new approach to the inflammatory/autoimmune diseases. Recent Pat. Antiinfect. Drug Discov. 4 (2009) 108-113
30. Eltzschig H.K., Eckle T., Mager A., Kuper N., Karcher C., Weissmuller T., Boengler K., Schulz R., Robson S.C., and Colgan S.P. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ. Res. 99 (2006) 1100-1108
31. Yang S., Cheek D.J., Westfall D.P., and Buxton I.L. Purinergic axis in cardiac blood vessels. Agonist-mediated release of ATP from cardiac endothelial cells. Circ. Res. 74 (1994) 401-407
32. Eltzschig H.K., Weissmuller T., Mager A., and Eckle T. Nucleotide metabolism and cell-cell interactions. Methods Mol. Biol. 341 (2006) 73-87
33. Berne R.M. The role of adenosine in the regulation of coronary blood flow. Circ. Res. 47 (1980) 807-813
34. Tanaka N., Nejime N., Kagota S., Kubota Y., Yudo K., Nakamura K., Kunitomo M., Takahashi K., Hashimoto M., and Shinozuka K. ATP participates in the regulation of microvessel permeability. J. Pharm. Pharmacol. 58 (2006) 481-487
35. 2+ signalling in vascular endothelial cells. Clin. Exp. Pharmacol. Physiol. 30 (2003) 649-652
36. McClenahan D., Hillenbrand K., Kapur A., Carlton D., and Czuprynski C. Effects of extracellular ATP on bovine lung endothelial and epithelial cell monolayer morphologies, apoptoses, and permeabilities. Clin. Vaccine Immunol. 16 (2009) 43-48
37. Chambers A.F., MacDonald I.C., Schmidt E.E., Morris V.L., and Groom A.C. Clinical targets for anti-metastasis therapy. Adv. Cancer Res. 79 (2000) 91-121
38. Steinbauer M., Guba M., Cernaianu G., Kohl G., Cetto M., Kunz-Schughart L.A., Geissler E.K., Falk W., and Jauch K.W. GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin. Exp. Metast. 20 (2003) 135-141
39. Schluter K., Gassmann P., Enns A., Korb T., Hemping-Bovenkerk A., Holzen J., and Haier J. Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am. J. Pathol. 169 (2006) 1064-1073
40. Glinsky V.V., Glinsky G.V., Rittenhouse-Olson K., Huflejt M.E., Glinskii O.V., Deutscher S.L., and Quinn T.P. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 61 (2001) 4851-4857
41. Glinskii O.V., Huxley V.H., Glinsky G.V., Pienta K.J., Raz A., and Glinsky V.V. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7 (2005) 522-527
42. Chambers A.F., Naumov G.N., Varghese H.J., Nadkarni K.V., MacDonald I.C., and Groom A.C. Critical steps in hematogenous metastasis: an overview. Surg. Oncol. Clin. N Am. 10 (2001) 243-255 (vii)
43. Miles F.L., Pruitt F.L., van Golen K.L., and Cooper C.R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metast. 25 (2008) 305-324
44. Blay J., White T.D., and Hoskin D.W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57 (1997) 2602-2605
45. Spychala J. Tumor-promoting functions of adenosine. Pharmacol. Ther. 87 (2000) 161-173
46. Spychala J., Lazarowski E., Ostapkowicz A., Ayscue L.H., Jin A., and Mitchell B.S. Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin. Cancer Res. 10 (2004) 708-717
47. Rumjahn S.M., Javed M.A., Wong N., Law W.E., and Buxton I.L. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br. J. Cancer 97 (2007) 1372-1380
48. Anzinger J., Malmquist N.A., Gould J., and Buxton I.L. Secretion of a nucleoside diphosphate kinase (Nm23-H2) by cells from human breast, colon, pancreas and lung tumors. Proc. West Pharmacol. Soc. 44 (2001) 61-63
49. Oxhorn B.C., Cheek D.J., and Buxton I.L. Role of nucleotides and nucleosides in the regulation of cardiac blood flow. AACN Clin. Issues 11 (2000) 241-251
50. Bogle R.G., Coade S.B., Moncada S., Pearson J.D., and Mann G.E. Bradykinin and ATP stimulate l-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem. Biophys. Res. Commun. 180 2 (1991) 926-932
51. Mehta A., and Orchard S. Nucleoside diphosphate kinase (NDPK, NM23, AWD): recent regulatory advances in endocytosis, metastasis, psoriasis, insulin release, fetal erythroid lineage and heart failure; translational medicine exemplified. Mol. Cell Biochem. 329 (2009) 3-15
52. Bosnar M.H., Bago R., and Cetkovic H. Subcellular localization of Nm23/NDPK A and B isoforms: a reflection of their biological function?. Mol. Cell Biochem. 329 (2009) 63-71
53. Malmquist N.A., Anzinger J.J., Hirzel D., and Buxton I.L. Ellagic acid inhibits nucleoside diphosphate kinase-B activity. Proc. West Pharmacol. Soc. 44 (2001) 57-59
54. Rumjahn S.M., Baldwin K.A., and Buxton I.L. P2y receptor-mediated angiogenesis via vascular endothelial growth factor receptor 2 signaling. Proc. West Pharmacol. Soc. 50 (2007) 58-60
55. Rumjahn S.M., Yokdang N., Baldwin K.A., Thai J., and Buxton I.L. Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis. Br. J. Cancer 100 (2009) 1465-1470
56. Packham M.A., Ardlie N.G., and Mustard J.F. Effect of adenine compounds on platelet aggregation. Am. J. Physiol. 217 4 (1969) 1009-1017
57. Soslau G., Brodsky I., and Parker J. Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets. Biochim. Biophys. Acta Mol. Cell Res. 1177 (1993) 199-207
58. Rubio R., Wiedmeier V.T., and Berne R.M. Relationship between coronary flow and adenosine production and release. J. Mol. Cell Cardiol. 6 (1974) 561-566
59. Gordon E.L., Pearson J.D., and Slakey L.L. The hydrolysis of extracellular adenine nucleotides by cultured endothelial cells from pig aorta. Feed-forward inhibition of adenosine production at the cell surface. J. Biol. Chem. 261 (1986) 15496-15507
60. White N., and Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 27 (2006) 211-217
61. Hopfner M., Lemmer K., Jansen A., Hanski C., Riecken E.O., Gavish M., Mann B., Buhr H., Glassmeier G., and Scherubl H. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem. Biophys. Res. Commun. 251 (1998) 811-817
62. Coutinho-Silva R., Stahl L., Cheung K.K., de Campos N.E., de Oliveira Souza C., Ojcius D.M., and Burnstock G. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am. J. Physiol. Gastr. Liver Physiol. 288 (2005) G1024-G1035
63. Bautch V.L., and Ambler C.A. Assembly and patterning of vertebrate blood vessels. Trends Cardiovasc. Med. 14 (2004) 138-143
64. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
65. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
66. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
67. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971) 1182-1186
68. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995) 149-153
69. Duncker D.J., and Bache R.J. Regulation of coronary blood flow during exercise. Physiol. Rev. 88 (2008) 1009-1086
70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
71. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
72. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
73. Rastinejad F., Polverini P.J., and Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56 (1989) 345-355
74. Udagawa T., Fernandez A., Achilles E.G., Folkman J., and D'Amato R.J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16 (2002) 1361-1370
75. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
76. Kesisis G., Broxterman H., and Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr. Pharm. Des. 13 (2007) 2795-2809
77. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
78. Buxton I.L.O. Inhibition of nm23 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. Proc. Western Pharmacol. Soc. 51 (2008) 30-34
79. Brown A.P., Citrin D.E., and Camphausen K.A. Clinical biomarkers of angiogenesis inhibition. Cancer Metast. Rev. 27 (2008) 415-434
80. Gonzalez-Angulo A.M., Morales-Vasquez F., and Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608 (2007) 1-22
81. Poncet B., Bachelot T., Colin C., Ganne C., Jaisson-Hot I., Orfeuvre H., Peaud P.Y., Jacquin J.P., Salles B., Tigaud J.D., Mechin-Cretinon I., Marechal F., Fournel C., and Trillet-Lenoir V. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am. J. Clin. Oncol. 31 (2008) 363-368
82. Kolesar J.M. Bevacizumab: improved survival at what cost?. Am. J. Health Syst. Pharm. 62 (2005) 1017
83. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., and Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61 (2001) 5090-5101
84. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
85. I. National Cancer, Angiogenesis Inhibitors in Cancer Research, 1999.
86. I. National Cancer, SEER Cancer Statistics Review 1975-2005, 2008.
87. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
88. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta 455 (1976) 152-162
89. Ueda K., Cardarelli C., Gottesman M.M., and Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84 (1987) 3004-3008
90. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De W.J., Martinive P., Gregoire V., Feron O., and Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11 (2005) 743-750
91. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
92. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
93. Kruck S., Kuczyk M.A., Gakis G., Kramer M.W., Stenzl A., and Merseburger A.S. Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. Rev. Recent Clin. Trials 3 (2008) 212-216
94. Burnstock G. Vascular control of purines with emphasis on the coronary system. Eur. Heart J. 10 (1989) 15-21
95. Buxton I.L., Kaiser R.A., Oxhorn B.C., and Cheek D.J. Evidence supporting the Nucleotide Axis Hypothesis: ATP release and metabolism by coronary endothelium. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1657-H1666
96. Bodin P., and Burnstock G. ATP-stimulated release of ATP by human endothelial cells. J. Cardiovasc. Pharm. 27 (1996) 872-875
97. Ellsworth M.L., Ellis C.G., Goldman D., Stephenson A.H., Dietrich H.H., and Sprague R.S. Erythrocytes: oxygen sensors and modulators of vascular tone. Physiol. (Bethesda.) 24 (2009) 107-116
98. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
99. von Kugelgen I., and Wetter A. Molecular pharmacology of P2Y-receptors. N.-S. Arch. Pharmacol. 362 (2000) 310-323
100. Ivanov A.A., Ko H., Cosyn L., Maddileti S., Besada P., Fricks I., Costanzi S., Harden T.K., Calenbergh S.V., and Jacobson K.A. Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate. J. Med. Chem. 50 (2007) 1166-1176
101. Jacobson K.A., Costanzi S., Ohno M., Joshi B.V., Besada P., Xu B., and Tchilibon S. Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr. Top. Med. Chem. 4 (2004) 805-819
102. Kaczmarek E., Koziak K., Sevigny J., Siegel J.B., Anrather J., Beaudoin A.R., Bach F.H., and Robson S.C. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem. 271 (1996) 33116-33122
103. Rugonyi S. Effect of blood flow on near-the-wall mass transport of drugs and other bioactive agents: a simple formula to estimate boundary layer concentrations. J. Biomech. Eng. 130 (2008) 021010
104. Gorman M.W., Ogimoto K., Savage M.V., Jacobson K.A., and Feigl E.O. Nucleotide coronary vasodilation in guinea pig hearts. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H1040-H1047
105. Erlinge D., and Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic. Signal. 4 (2008) 1-20
106. Gorman M.W., Marble D.R., Ogimoto K., and Feigl E.O. Measurement of adenine nucleotides in plasma. Luminescence 18 (2003) 173-181
107. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 58 (2006) 58-86
108. George S., Dreicer R., Au J.J., Shen T., Rini B.I., Roman S., Cooney M.M., Mekhail T., Elson P., Wientjes G.M., Ganapathi R., and Bukowski R.M. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 6 (2008) 79-85
109. Smaldone M.C., Gayed B.A., Tomaszewski J.J., and Gingrich J.R. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol. Nefrol. 61 (2009) 71-89
110. Hotz B., Buhr H.J., and Hotz H.G. Intravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer. J. Gastr. Surg. 12 (2008) 900-906
111. Bhargava S., Hotz B., Hines O.J., Reber H.A., Buhr H.J., and Hotz H.G. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J. Gastr. Surg. 11 (2007) 171-178
112. Suganuma M., Okabe S., Kai Y., Sueoka N., Sueoka E., and Fujiki H. Synergistic effects of (--)-epigallocatechin gallate with (--)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 59 (1999) 44-47
113. Cao Y., and Cao R. Angiogenesis inhibited by drinking tea. Nature 398 (1999) 381
114. Singh A.K., Seth P., Anthony P., Husain M.M., Madhavan S., Mukhtar H., and Maheshwari R.K. Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch. Biochem. Biophys. 401 (2002) 29-37
115. Yamakawa S., Asai T., Uchida T., Matsukawa M., Akizawa T., and Oku N. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett. 210 (2004) 47-55
116. Kazi A., Wang Z., Kumar N., Falsetti S.C., Chan T.H., and Dou Q.P. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 24 (2004) 943-954
117. Postel E.H. Multiple biochemical activities of NM23/NDP kinase in gene regulation. J. Bioenergy Biomembr. 35 (2003) 31-40
118. McDermott W.G., Boissan M., Lacombe M.L., Steeg P.S., and Horak C.E. Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth. Clin. Exp. Metast. 25 (2008) 131-138
119. Bertheua P., Merino M., Steeg P., and DeLaRosa A. NM23 protein in neoplastic and nonneoplastic thyroid tissues. Am. J. Pathol. 145 (1994) 26-32
120. Steeg P.S., Bevilacqua G., Kopper L., Thorgeirsson U.P., Talmadge J.E., Liotta L.A., and Sobel M.E. Evidence for a novel gene associated with low tumor metastatic potential. J. Nat. Cancer Inst. 80 3 (1988) 200-204
121. Heimann R., Ferguson D.J., and Hellman S. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res. 58 (1998) 2766-2771
122. Palmieri D., Horak C.E., Lee J.H., Halverson D.O., and Steeg P.S. Translational approaches using metastasis suppressor genes. J. Bioenergy Biomembr. 38 (2006) 151-161
123. Okabe-Kado J., Kasukabe T., Honma Y., Hanada R., Nakagawara A., and Kaneko Y. Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci. 96 (2005) 653-660
124. Niitsu N., Nakamine H., Okamoto M., Tamaru J.I., and Hirano M. A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Ann. Oncol. 19 (2008) 1941-1946
125. Roymans D., Willems R., Van Blockstaele D.R., and Slegers H. Nucleoside diphosphate kinase (NDPK/NM23) and the waltz with multiple partners: possible consequences in tumor metastasis. Clin. Exp. Metast. 19 (2002) 465-476
126. Sauer T., Furu I., Beraki K., Jebsen P.W., Ormerod E., and Naess O. nm23 protein expression in fine-needle aspirates from breast carcinoma: inverse correlation with cytologic grading, lymph node status, and ploidy. Cancer 84 (1998) 109-114
127. Russell R.L., Geisinger K.R., Mehta R.R., White W.L., Shelton B., and Kute T.E. nm23-relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients. Cancer 79 (1997) 1158-1165
128. Sawan A., Lascu I., Veron M., Anderson J.J., Wright C., Horne C.H.W., and Angus B. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J. Pathol. 172 (1994) 27-34
129. Lazarowski E.R., Boucher R.C., and Harden T.K. Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J. Biol. Chem. 275 (2000) 31061-31068
130. Lazarowski E.R., Homolya L., Boucher R.C., and Harden T.K. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J. Biol. Chem. 272 (1997) 20402-20407
131. Hamby C.V., Abbi R., Prasad N., Stauffer C., Thomson J., Mendola C.E., Sidorov V., and Backer J.M. Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells. Int. J. Cancer 88 (2000) 547-553
132. Huwer H., Kalweit G., Engel M., Welter C., Dooley S., and Gams E. Expression of the candidate tumor suppressor gene nm23 in the bronchial system of patients with squamous cell lung cancer. Eur. J. Cardiothorac. Surg. 11 (1997) 206-209
133. Niitsu N., Okabe-Kado J., Okamoto M., Takagi T., Yoshida T., Aoki S., Hirano M., and Honma Y. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97 (2001) 1202-1210
134. Okabe-Kado J., Kasukabe T., and Honma Y. Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia. Leuk. Lymphoma 32 (1998) 19-28
135. Okabe-Kado J., Kasukabe T., and Honma Y. Expression of cell surface NM23 proteins of human leukemia cell lines of various cellular lineage and differentiation stages. Leuk. Res. 26 (2002) 569-576
136. Jackson S.W., Hoshi T., Wu Y., Sun X., Enjyoji K., Cszimadia E., Sundberg C., and Robson S.C. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am. J. Pathol. 171 (2007) 1395-1404
137. Goepfert C., Sundberg C., Sevigny J., Enjyoji K., Hoshi T., Csizmadia E., and Robson S. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104 (2001) 3109-3115
138. Kaiser R.A., and Buxton I.L. Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. Br. J. Pharamcol. 135 (2002) 537-545
139. Kaiser R.A., Oxhorn B.C., Andrews G., and Buxton I.L. Functional compartmentation of endothelial P2Y receptor signaling. Circ. Res. 91 (2002) 292-299
140. Kashiwagi S., Izumi Y., Gohongi T., Demou Z.N., Xu L., Huang P.L., Buerk D.G., Munn L.L., Jain R.K., and Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115 (2005) 1816-1827
141. Fishman P., Bar-Yehuda S., Synowitz M., Powell J.D., Klotz K.N., Gessi S., and Borea P.A. Adenosine receptors and cancer. Handb. Exp. Pharmacol. (2009) 399-441
142. Deli T., and Csernoch L. Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol. Oncol. Res. 14 (2008) 219-231
143. Shabbir M., and Burnstock G. Purinergic receptor-mediated effects of adenosine 5′-triphosphate in urological malignant diseases. Int. J. Urol. 16 (2009) 143-150
144. Kaczmarek E., Erb L., Koziak K., Jarzyna R., Wink M.R., Guckelberger O., Blusztajn J.K., Trinkaus-Randall V., Weisman G.A., and Robson S.C. Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb. Haemostasis 93 (2005) 735-742
145. Satterwhite C.M., Farrelly A.M., and Bradley M.E. Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells. Am. J. Physiol. 276 (1999) H1091-H1097
146. 2+ dependent manner. Life Sci. 72 (2003) 1445-1453
147. Tanaka N., Kawasaki K., Nejime N., Kubota Y., Nakamura K., Kunitomo M., Takahashi K., Hashimoto M., and Shinozuka K. P2Y receptor-mediated Ca(2+) signaling increases human vascular endothelial cell permeability. J. Pharmacol. Sci. 95 (2004) 174-180
148. Seye C.I., Yu N., Gonzalez F.A., Erb L., and Weisman G.A. The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J. Biol. Chem. 279 (2004) 35679-35686
149. Buvinic S., Bravo-Zehnder M., Boyer J.L., Huidobro-Toro J.P., and Gonzalez A. Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells. J. Cell Sci. 120 (2007) 4289-4301
150. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39 (2006) 469-478
151. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
152. Moses M.A. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15 (1997) 180-189
153. Hirschi K.K., and D'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. 32 (1996) 687-698
154. Grant D.S., and Kleinman H.K. Regulation of capillary formation by laminin and other components of the extracellular matrix. EXS 79 (1997) 317-333
155. Gerwins P., Skoldenberg E., and Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 34 (2000) 185-194
156. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001 (2001) RE21
157. Folberg R., Hendrix M.J., and Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156 (2000) 361-381
158. Shirakawa K., Wakasugi H., Heike Y., Watanabe I., Yamada S., Saito K., and Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int. J. Cancer 99 (2002) 821-828
159. Shirakawa K., Shibuya M., Heike Y., Takashima S., Watanabe I., Konishi F., Kasumi F., Goldman C.K., Thomas K.A., Bett A., Terada M., and Wakasugi H. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int. J. Cancer 99 (2002) 344-351
160. Yue W.Y., and Chen Z.P. Does vasculogenic mimicry exist in astrocytoma?. J. Histochem. Cytochem. 53 (2005) 997-1002
161. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., McLaren J., Barker P.J., Wright K.A., Twentyman P.R., and Smith S.K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Nat. Cancer Inst. 87 (1995) 506-516
162. Wang L., Karlsson L., Moses S., Hultgardh-Nilsson A., Andersson M., Borna C., Gudbjartsson T., Jern S., and Erlinge D. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J. Cardiovasc. Pharm. 40 (2002) 841-853
163. Cho C.H., Lee C.S., Chang M., Jang I.H., Kim S.J., Hwang I., Ryu S.H., Lee C.O., and Koh G.Y. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1881-H1888
164. Labrecque L., Royal I., Surprenant D.S., Patterson C., Gingras D., and Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 14 (2003) 334-347
165. Ikeda S., Ushio-Fukai M., Zuo L., Tojo T., Dikalov S., Patrushev N.A., and Alexander R.W. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 96 (2005) 467-475
166. Massimino M.L., Griffoni C., Spisni E., Toni M., and Tomasi V. Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis. Cell Signal. 14 (2002) 93-98
167. Soslau G., McKenzie R.J., Brodsky I., and Devlin T.M. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets. Biochem. Biophys. Acta 1268 (1995) 73-80
168. Cristalli G., Vittori S., Thompson R.D., Padgett W.L., Shi D., Daly J.W., and Olsson R.A. Inhibition of platelet aggregation by adenosine receptor agonists. N.-S. Arch. Pharmacol. 349 (1994) 644-650
169. Berne R.M. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am. J. Physiol. 204 2 (1963) 317-322
170. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., and Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130 (2007) 691-703